Concord Drugs Ltd - 538965 - Shareholding for the Period Ended September 30, 2020
Concord Drugs Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2020. For more details, kindly Click here21-10-2020
21-10-2020
Concord Drugs Ltd - 538965 - Statement Of Investor Complaints For The Quarter Ended September 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Jyoti GoyalDesignation :- Company Secretary and Compliance Officer21-10-2020
Concord Drugs Ltd - 538965 - Information Under Regulation 30 Of SEBI (LODR) Regulations, 2015
Information under regulation 30 of SEBI (LODR) Regulations, 201513-10-2020
Concord Drugs Ltd - 538965 - Closure of Trading Window
Closure of Trading window for Quarter ended 30.09.202029-09-2020
Concord Drugs Ltd - 538965 - Outcome Of Board Meeting Held On 14.09.2020
Outcome of Board Meeting held on 14.09.202014-09-2020
Concord Drugs Ltd - 538965 - Board Meeting Intimation for Unaudited Financial Results For The Quarter Ended 30.06.2020
Concord Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/09/2020 ,inter alia, to consider and approve unaudited financial results and Limited Review Report for the Quarter ended 30.06.202004-09-2020
Concord Drugs Ltd - 538965 - Shareholding for the Period Ended June 30, 2020
Concord Drugs Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2020. For more details, kindly Click here20-07-2020
Concord Drugs Ltd - 538965 - Statement Of Investor Complaints For The Quarter Ended June 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- NAGI REDDY SEELAMDesignation :- Managing Director / Whole Time Director20-07-2020
Concord Drugs Ltd - 538965 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate u/r 74(5) of SEBI (DP) Regulations, 201820-07-2020
Concord Drugs Ltd - 538965 - Statement Of Cash Flows For The Year Ended 31.03.2020
Statement of cash flows for the year ended 31.03.202030-06-2020